Exelixis Soars 12.8% (EXEL)

Shares of Exelixis, Inc. EXEL are currently up 12.8% at $8.14 per share during Wednesday afternoon trading. Today's trading range for shares of Exelixis, Inc has been between $7.12 and a 52-week high of $8.27 per share. The consensus price target of analysts covering the company's stock is $7.75 per share. Volume of 3.9 million shares is already more than double the daily average volume of 1.5 million shares. Exelixis, Inc. (EXEL) is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer. Read more from Benzinga's Company news.